BRAIN Biotech AG (LTS:0RFI) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RFI BRAIN Biotech AG LTS:0RFI
60 GF Score
Price €2.91
GF Value €2.70
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0RFI vs LIN, SHW, ECL: Short Interest Comparison

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG Short Interest vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Short Interest distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Short Interest falls into.


LTS:0RFI
60GF Score
BRAIN Biotech AG LTS:0RFI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BRAIN Biotech AG (LTS:0RFI) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.91 is trading 7.8% above its estimated GF Value™ of €2.70. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for LTS:0RFI:

  • Short Interest:
  • GF Value™: €2.70 vs. price of €2.91 (7.8% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RFI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges BNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
60GF Score

Get the complete analysis for LTS:0RFI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.91
Price
€2.70
GF Value